

## **Appendix 4C and Activities Report: Stable Receipts, Growth in Key Divisions, Update of Collagen Business and Board & Leadership Appointments**

### **ASX Announcement**

**29 July 2025**

### **Highlights**

- **Customer Receipts Maintained** — \$1.65 million recorded for the quarter, demonstrating consistency compared to the same period last year
- **Dietary Supplements Division Growth** — Recorded sales of \$861K, a 38% increase over 2QFY24, supported by a stabilized sales team, enhanced marketing efforts, and favorable currency movements.
- **Collagen Division Moves Up the Value Chain** – The Group has updated significant developments relating to production and marketing of nano-collagen for advanced medical applications.
- **Board Appointments**— Mr. Lai Kwok Kin, an Independent Director, was appointed Independent Non-Executive Chairman, while Mr. Robert Gemelli and Mr. Sam Yee were appointed as Independent Non-Executive Directors.
- **New Chief Executive Officer** — Following his appointment as interim CEO since 3<sup>rd</sup> January 2025, Mr. Leong Man Loong, an Executive Director, was appointed as Chief Executive Officer (“CEO”).


---

### **Quarterly Update and Commentary**

**Holista Colltech Limited** (ASX:HCT, “**Holista**” or, the “**Group**”) is pleased to present this quarterly update alongside its Appendix 4C for the three months ended 30 June 2025 (“**2QFY25**”). This period reflects continued momentum in our core operations, including positive sales trends and significant developments of the collagen business, amid changes to the Board and the appointment of a Chief Executive Officer (“CEO”).

## Financial Overview

Operating cash outflows improved to \$1.9 million, a 40% reduction from 1QFY25, underscoring effective cost management and normalisation of expenses after settlement of the second and final ASIC penalty in March 2025.



*\*All sales figures are subject to audit.*

As at 30 June 2025, the Company maintained a cash balance of \$42K. This is supported by reliable monthly receipts from our largest dietary supplements distributor, Zuellig Pharma, at the beginning of every month. Typically, we receive between \$300K and \$400K monthly from prior month's sales.

Including the cash balance and \$1.1 million in unused credit lines, the Company's available financing facilities total \$1.15 million. This provides an estimated 4.79 quarters of funding availability to support ongoing operations and growth initiatives.

The Company remains committed to proactive funding management, ensuring alignment with our strategic objectives and operational excellence.

In accordance with ASX Listing Rule 4.7C, payments of \$97K were made to related parties and their associates during the quarter.

## Divisional Performance


Group sales increased 15.8% Year-on-Year ("YoY") to \$1.085 million, supported by pricing adjustments in March 2025, resilient demand across our divisions and favourable currency conditions. The quarter-on-quarter ("QoQ") variation reflects temporary accounting standard adjustments. Underlying momentum remains strong with the Dietary Supplements Division remaining the primary revenue driver.

- **Dietary Supplements Division** — Revenue rose 38% YoY to \$861K, propelled by a revitalised sales and marketing team and favourable currency

translation. This growth underscores our ability to capture market opportunities and build on our established brand strength.

- **Food Ingredients Division** — Generated \$192K in revenue, signalling a positive recovery in orders from key customer Rex.
- **Ovine Collagen Division** — Achieved steady revenue of \$32K, maintaining consistency and laying the foundation for future expansion.  
On 27 May 2025, the Board announced an update of its collagen business, including:
  - i) the cessation of activities at Collie;
  - ii) efforts to develop higher-value nano-collagen to target advanced medical applications, and related intellectual property applications;
  - iii) licensing agreement with Regenerex to market nano-collagen; and
  - iv) a proposal to establish a dedicated nano-collagen facility in Sarawak.
 The Company continues to pursue this multi-action strategy and will update in due course.
- **Infection Control/Agriculture Division** – No sales recorded for the quarter. Management will continue to evaluate opportunities.

We remained focused on cost control and internal efficiencies, innovation and optimising our product portfolio to meet evolving market needs. We continue to monitor operations closely, ensuring alignment with cash flow priorities and long-term value creation for shareholders.



*\*All sales figures are subject to audit*

### Investing and Financing Activities

Holista upheld prudent stewardship of its investing and financing activities during the quarter:

- **Investing Activities:** Recorded a modest \$18K cash outflow, primarily linked to a fixed deposit associated with our banking arrangements, reflecting strategic asset management.
- **Financing Activities:** Noted a net cash outflow of \$18K, which included a \$24K foreign exchange gain on convertible notes from 1QFY25, offset by \$42K in loan repayments, demonstrating our commitment to financial discipline and balance sheet strength.

## Corporate Updates

The following significant leadership changes have taken place recently:

- Non-Executive Chairman Mr. David Deloub and Non-Executive Director Ms. Loren King stepped down from the Board on 16 April 2025. The Board extends its sincere appreciation for their past contributions.
- Mr. Lai Kwok Kin was appointed as Independent Non-Executive Chairman, succeeding Mr. David Deloub, providing continuity in the Board leadership.
- Effective 14 May 2025, we welcomed Mr. Robert Gemelli and Mr. Sam Yee as Independent Non-Executive Directors, bringing diverse expertise to support our growth ambitions.
- Mr. Leong Man Loong, an Executive Director with deep experience in business and corporate matters, was appointed Chief Executive Officer effective 3 July 2025.

This announcement has been approved by the Board of Directors.

**-ENDS-**

## About Holista Colltech Limited

Holista Colltech Limited (ASX: HCT) is a Perth-based innovator in health and wellness solutions. Operating across four dynamic business divisions—Dietary Supplements, Healthy Food Ingredients, Ovine Collagen, and Infection Control/Agriculture Solutions—Holista delivers cutting-edge products that blend nature and science for healthier lifestyles.

Our portfolio features leading nutritional supplements, patented low-GI food ingredients, premium disease-free ovine collagen, and eco-friendly, non-toxic sanitizers for everyday and industrial use. We are dedicated to sustainable, science-driven solutions that empower better living and create lasting value for our stakeholders worldwide.

**For further information, please contact:**

Our Investor Mailing list: [investors@holistaco.com](mailto:investors@holistaco.com)

General Enquiries: [enquiries@holistaco.com](mailto:enquiries@holistaco.com)

**Australia**

283 Rokeby Road  
Subiaco WA 6008 Western Australia  
Australia  
P: +61 412 474 180

**Malaysia**

12th Floor, Amcorp Trade Centre, PJ  
Tower No. 18, Persiaran Barat off Jalan  
Timur 46000, Petaling Jaya, Malaysia  
P: +603 7965 2828; F: +603 7965 2777

For personal use only

## Appendix 4C

### Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

**HOLISTA COLLTECH LIMITED (ASX: HCT)**

ABN

**24 094 515 992**

Quarter ended ("current quarter")

**30 June 2025**

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
<b>1.</b>	<b>Cash flows from operating activities</b>		
1.1	Receipts from customers	1,648	3,564
1.2	Payments for:		
	(a) research and development	(8)	(20)
	(b) product manufacturing and operating costs	(879)	(2,047)
	(c) advertising and marketing	(262)	(582)
	(d) leased assets	-	-
	(e) staff costs	(544)	(1,037)
	(f) administration and corporate costs	(136)	(362)
1.3	Dividends received (see note 3)	-	-
1.4	Interest received	1	1
1.5	Interest and other costs of finance paid	(32)	(58)
1.6	Income taxes paid	(28)	(65)
1.7	Government grants and tax incentives	-	-
1.8	Other (ASIC Penalty)	-	(900)
<b>1.9</b>	<b>Net cash from / (used in) operating activities</b>	<b>(240)</b>	<b>(1,506)</b>
<b>2.</b>	<b>Cash flows from investing activities</b>		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(6)	(6)
	(d) investments	(12)	(23)
	(e) intellectual property	-	-
	(f) other non-current assets	-	-

<b>Consolidated statement of cash flows</b>		<b>Current quarter \$A'000</b>	<b>Year to date (6 months) \$A'000</b>
2.2	Proceeds from the disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) Investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
<b>2.6</b>	<b>Net cash from / (used in) investing activities</b>	<b>(18)</b>	<b>(29)</b>
<b>3.</b>	<b>Cash flows from financing activities</b>		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	-	-
3.2	Proceeds from issue of convertible debt securities	**24	1,552
3.3	Proceeds from exercise of share options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	-	-
3.5	Proceeds from borrowings	1,780	3,308
3.6	Repayment of borrowings	(1,822)	(3,295)
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
<b>3.10</b>	<b>Net cash from / (used in) financing activities</b>	<b>(18)</b>	<b>1,565</b>
<b>4.</b>	<b>Net increase / (decrease) in cash and cash equivalents for the period</b>		
4.1	Cash and cash equivalents at beginning of period	355	22
4.2	Net cash from / (used in) operating activities (item 1.9 above)	(240)	(1,506)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(18)	(29)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	(18)	1,565
4.5	Effect of movement in exchange rates on cash held	(37)	(10)
<b>4.6</b>	<b>Cash and cash equivalents at end of period</b>	<b>42</b>	<b>42</b>

\*\*Forex adjustment

## Quarterly cash flow report for entities subject to Listing Rule 4.7B

<b>5.</b>	<b>Reconciliation of cash and cash equivalents</b> at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	<b>Current quarter \$A'000</b>	<b>Previous quarter \$A'000</b>
5.1	Bank balances	42	355
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (Restricted Cash)	-	-
<b>5.5</b>	<b>Cash and cash equivalents at end of quarter (should equal item 4.6 above)</b>	<b>42</b>	<b>355</b>

<b>6.</b>	<b>Payments to related parties of the entity and their associates</b>	<b>Current quarter \$A'000</b>
6.1	Aggregate amount of payments to related parties and their associates included in item 1	97
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-
<p><i>Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.</i></p> <p>Fees include Salaries, Director Fees and Consulting Fees to Executive Director and Non-Executive Directors</p>		

7.	<b>Financing facilities</b> <i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>	<b>Total facility amount at quarter end \$A'000</b>	<b>Amount drawn at quarter end \$A'000</b>
7.1	Loan facilities	454	454
7.2	Credit standby arrangements	2,355	1,247
7.3	Other (please specify)		
7.4	<b>Total financing facilities</b>	<b>2,809</b>	<b>1,701</b>
7.5	<b>Unused financing facilities available at quarter end</b>		<b>1,108</b>
7.6	Include in the box below a summary of each finance facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		
	<b>Summary of Banking Facilities:</b>		
	<b><u>Bank Loan Facility 1:</u></b>		
	<b>Parties:</b> CIMB Islamic Bank Berhad Malaysia ( <b>Banker</b> ), and Holista Biotech Sdn Bhd (100% subsidiary of Holista Collect Ltd) ( <b>Borrower</b> ).		
	<b>i) Loan Facility 1</b>		
	<b>Term Loan</b>		
	<b>Principal Amount:</b> MYR 1.4M / approximately A\$507k		
	<b>Remaining Payable as at 30 June 2025:</b> MYR 1.15M / approximately A\$417k		
	<b>Term:</b> Commencing on 1 October 2020 and repayable over 240 monthly instalments (principal plus interest) of \$3,207 (2024: \$3,186) and ending in 200 months on 4 October 2040.		
	<b>Interest Rate:</b> 3.74% per annum (2024: 3.74%).		
	<b>ii) Credit Standby Arrangement 1</b>		
	Trade Financing and Banker Acceptances bears interest of 5.18% per annum (2024: 5.07%).		
	<b>Total Amount at Quarter End:</b> MYR 2M / Approximately A\$724k		
	<b>Total Utilised at Quarter End:</b> MYR 1.978K / Approximately A\$717k		
	Bank Loan Facility 1 is secured by the following:		
	<ul style="list-style-type: none"> <li>• Fixed deposit with a licensed bank of the Group and the Company;</li> <li>• Facility agreement;</li> <li>• First party assignment over the office lots of the Company;</li> <li>• Deed of assignment of rental proceeds;</li> <li>• Executed fresh letter of authorisation, memorandum of deposit and letter of off-set; and</li> <li>• Guarantee by a director of the Company.</li> </ul>		
	Bank Loan Facility 1 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes:		
	<ul style="list-style-type: none"> <li>• "<b>Accepted Bills-i</b>", to facilitate local and export sales of the Borrower;</li> <li>• "<b>Multi Currency Trade Financing-i</b>", to facilitate local and export sales of the Borrower; and</li> <li>• "<b>Bank Guarantee</b>", for issuance of financial, performance and security bonds to government and private entities, in relation to business.</li> </ul>		

**Bank Loan Facility 2:**

**Parties:** CIMB Islamic Bank Berhad (**Banker**), and Total Health Concepts Sdn Bhd (100% subsidiary of Holista Biotech Sdn Bhd) (**Borrower**).

**i) Loan Facility 2****Term Loan**

**Principal Amount:** MYR 200K / approximately A\$72K.

**Amount Remaining as at 30 June 2025:** MYR 101k / approximately A\$37k

**Term:** Commencing on 28 September 2022 and repayable over 60 monthly instalments (principal plus interest) of \$1,423 (2024: \$1,413) and ending in 44 months on 4 November 2027.

**Interest Rate:** 6.60% per annum (2024: 6.60%).

**ii) Credit Standby Arrangement 2**

**Trade Financing and Banker Acceptance** bears interest of 5.19% per annum (2024: 5.09%).

**Total Amount at Quarter End:** MYR 1.5M / Approximately A\$543k

**Total Utilised at Quarter End:** MYR 1.465K / Approximately A\$531k

Bank Loan Facility 2 is secured by the following:

- Fixed deposit with a licensed bank of the Group and the Company;
- Assignment of director insurance;
- Corporate guarantee; and
- Guarantee by a director of the Company.

Bank Loan Facility 2 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes:

- “**Accepted Bills-i**”, to facilitate local and export sales of the Borrower;
- “**Multi Currency Trade Financing-i**”, to facilitate local and export sales of the Borrower;
- “**Documentary Credit-i**”, to facilitate local and import purchases of the Borrower;
- “**Accepted Bills-i 2**”, to facilitate local and import purchases of the Borrower; and
- “**Multi Currency Trade Financing-i 2**”, to facilitate local and import purchases of the Borrower.

**Bank Loan Facility 3:**

**Parties:** CIMB Islamic Bank Berhad (**Banker**), and Total Health Concepts Sdn Bhd (100% subsidiary of Holista Biotech Sdn Bhd) (**Borrower**).

**i) Credit Standby Arrangement 3**

Trade Financing and Banker Acceptance bears interest of 5.09% per annum.

**Total Amount at Quarter End:** MYR 3.0M / Approximately A\$1,087k

**Total Utilised at Quarter End:** MYR nil / Approximately A\$ nil

Bank Loan Facility 3 is secured by the following:

- Fixed deposit with a licensed bank of the Group and the Company.

Bank Loan Facility 3 is not a revolving credit facility that can be used for any purpose, with terms providing that the facility may only be drawn down by the Borrower for the following purposes:

- “**Accepted Bills-i**”, to facilitate local and export sales of the Borrower;
- “**Multi-Currency Trade Financing-i**”, to facilitate local and export sales of the Borrower;
- “**Documentary Credit-i**”, to facilitate local and import purchases of the Borrower;
- “**Accepted Bills-i 2**”, to facilitate local and import purchases of the Borrower; and
- “**Multi-Currency Trade Financing-i 2**”, to facilitate local and import purchases of the Borrower.

<b>8. Estimated cash available for future operating activities</b>	<b>\$A'000</b>
8.1 Net cash from / (used in) operating activities (item 1.9)	(240)
8.2 Cash and cash equivalents at quarter end (item 4.6)	42
8.3 Unused finance facilities available at quarter end (item 7.5)	1,108
8.4 Total available funding (item 8.2 + item 8.3)	<b>1,150</b>
<b>8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)</b>	<b>4.79</b>
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/A	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/A	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/A	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

## Compliance statement

- This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- This statement gives a true and fair view of the matters disclosed.

**Date:** 29 July 2025

**Authorised by:** The Board  
(Name of body or officer authorising release – see note 4)

### Notes

- This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
- If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, AASB 107: Statement of Cash Flows apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
- Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
- If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg Audit and Risk Committee]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
- If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's Corporate Governance Principles and Recommendations, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.